Cetirizine Hydrochloride
FDA Label NDC 12634-987
Structured Product Label
The following Structured Product Label (SPL) was submitted to the FDA by Apotheca Inc. for the product Cetirizine Hydrochloride (NDC 12634-987). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding active ingredient, purpose, uses, warnings, ask a doctor before use, ask a doctor or pharmacist before use, when using this product, stop use and ask a doctor, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Label Section Quick Index
Purpose
Uses
Temporarily relieves these symptoms due to hay fever or other upper respiratory allergies
- runny nose
- sneezing
- itchy, watery eyes
- itching of the nose or throat
Warnings
Ask A Doctor Before Use
Ask A Doctor Or Pharmacist Before Use
if you are taking tranquilizers or sedatives.
When Using This Product
- drowsines may occur
- avoid alcoholic drinks
- alcohol, sedatives, and tranquilizers may increase drowsiness
- be careful when driving a motor vehicle or operating
machinary.
Stop Use And Ask A Doctor
If Pregnant Or Breast-Feeding:
- if breast-feeding: not recommended
- if pregnant: ask a health professional before use.
Keep Out Of Reach Of Children.
In case of overdose, get medical help or contact Poison Control Center right away.
Directions
| Adults and children 6 years and over | one 10 mg tablet once daily, do not take more than one 10 mg tablet in 24 hours. |
| Adults 65 years and over | Ask a doctor |
| Children under 6 years of age | Ask a doctor |
| Consumers with liver or kidney disease | Ask a doctor |
Other Information And Inactive Ingredients
Questions
Monday though Friday 9AM – 2PM MST
Distributed by:
RejuviLife, Phoenix, AZ
RejuviLife is a trademark of Apotheca Inc.
Package Label And Principal Display Panel
* Please review the disclaimer below.